Effect of early bosentan administration on the development of esophageal varices in cirrhotic rats: Experimental study in Wistar rats

Journal of Gastroenterology

Volumn 43, Issue 11, 2008, Pages 897-904

  Rafailidis, Savas ^a,c   Ballas, Konstantinos ^a   Psarras, Kyriakos ^a   Pavlidis, Theodoros ^a   Emoniotou, Eleni ^a   Papamichali, Rodoula ^b   Kalodimos, Georges ^b   Marakis, Georges ^a   Sakadamis, Athanassios ^a   Koukoulis, Georges ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c NONE   (Greece)

Author keywords

Carbon tetrachloride; Endothelin receptors antagonists; Endothelins; Hepatic cirrhosis; Portal hypertension

Indexed keywords

BOSENTAN; CARBON TETRACHLORIDE; PHENOBARBITAL; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES FLUID; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFICACY; EARLY INTERVENTION; ESOPHAGUS MUCOSA; ESOPHAGUS VARICES; EXPERIMENTAL STUDY; HEMODYNAMICS; LIVER CIRRHOSIS; MALE; MORPHOMETRICS; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; VASCULARIZATION; VEIN DILATATION; VEIN LIGATION; WISTAR RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL AND GASTRIC VARICES; FOLLOW-UP STUDIES; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; PORTAL PRESSURE; RATS; RATS, WISTAR; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 56649120263     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-008-2243-0     Document Type: Article

References (37)

1. Gupta T, Chen L, Groszmann RJ. Pathophysiology of portal hypertension. Clin Gastroenterol 1997;11:203-220.
2. Paquet, K-J. Causes and pathomechanisms of oesophageal varices development. Med Sci Monit 2000;6:915-928.
3. Groszmann RJ, Abraldes JG. Portal hypertension. From bedside to bench. J Clin Gastroenterol 2005;39:S125-S130.
4. Bosch J, Pizcueta E, Feu F, Fernandez M, Garcia-Pagan JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am 1992;21:1-14.
5. Lin HC, Soubrane O, Cailmail S, Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal systemic shunting in conscious portal vein stenosed rats. J Hepatol 1991;13:213-219.
6. Sarin SK, Groszmann RJ, Mosca PG. Propranolol ameliorates the development of portal systemic shunting in a chronic murine schistosomiasis model of portal hypertension. J Clin Invest 1991;87:1032-1036.
7. Groszmann RJ, Bosch J, Grace ND. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of first variceal hemorrhage. Gastroenterology 1990;99:1401-1407.
8. Ballas KD, Tzioufa-Asimakopoulou V, Marakis G, Alatsakis MB, Papavasiliou AV, Rafailidis S, et al. Effect of early octreotide administration on the development of esophageal varices in cirrhotic rats. Hepatol Res 2004;29:104-112.
9. Uchihara M, Izumi N, Sato C, Marumo E. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology 1992;16:95-99.
10. Gandhi CR, Sproat LA, Subbotin VM. Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats. Life Sci 1996;58:55-62.
11. Zhang JX, Bauer M, Clemens MG. Vessel-and target cell-specific actions of endothelin-1 and endothelin-3 in rat liver. Am J Physiol 1995;269:G269-G277.
12. Rockey DC. Characterization of endothelin receptors mediating rat hepatic stellate cell contraction. Biochem Biophys Res Commun 1995;207:725-731.
13. Elliot AJ, Vo LT, Grossman VL, Blathal PS, Grossman HJ. Endothelin-induced vasoconstriction in isolated perfused liver preparations from normal and cirrhotic rats. J Gastroenterol Hepatol 1997;12:314-318.
14. Zhang B, Calmus Y, Wen L, Sogni P, Lotersztajn S, Houssin D, et al. Endothelin-1 induces liver vasoconstriction through both ETA and ETB receptors. J Hepatol 1997;26:1104-1110.
15. Sogni P, Moreau R, Gomola A, Gadano A, Cailmail S, Calmus Y, et al. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology 1998;28:655-659.
16. Reichen J, Gerbes AL, Steiner MJ, Saegesser H, Clozel M. The effect of endothelin and its antagonist bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol 1998;28:1020-1030.
17. Sakadamis A, Ballas K, Tzioufa-Asimakopoulou V, Alatsakis M. A rat model of liver cirrhosis and esophageal varices. Res Exp Med 2001;200:137-154.
18. Proctor E, Chatamra K. High yield micronodular cirrhosis in the rat. Gastroenterology 1982;83:1183-1190.
19. Proctor E, Chatamra K. Standardized micronodular cirrhosis in the rat. Eur Surg Res 1984;16:182-186.
20. Lee FY, Wang SS, Tsai YT, Chang FY, Lin HC, Hou MC, et al. Hemodynamic studies and esophageal morphometric analyses in portal hypertensive rats with adrenal vein ligation. Scand J Gastroenterol 1997;32:725-730.
21. Sarin SK, Stadeker M, Groszmann RJ. Propranolol prevents the development of portal systemic shunting in chronic murine schistosomiasis. Gastroenterology 1989;96:A654.
22. Ruthardt FW, Stauber RE, Kuhlen R, Ban Thiel DH. Chronic beta blockade reduces portal systemic shunting in portal hypertensive rats. Gastroenterology 1990;98:A199.
23. Lin H, Soubrane O, Lebrec D. Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein stenosed rats. Hepatology 1991;14:325-330.
24. Debaene B, Goldfarb G, Braillon A. Effects of ketamine, halothane, enflurane and isoflurane on systemic and splanchnic hemodynamics in normovolemic and hypovolemic cirrhotic rats. Anesthesiology 1990;73:118-124.
25. Zimpfer M, Manders WT, Barger AC, Vatner SF. Pentobarbital alters compensatory neural and humoral mechanisms in response to hemorrhage. Am J Physiol 1982;243:713-721.
26. Lee SS, Hadengue A, Girod C, Lebrec D. Discrepant responses to betaxolol in conscious and anaesthetized portal hypertensive rats. Hepatology 1986;3:S139.
27. Jenkins SA, Baxter JN, Shields R. The effects of a somatostatin analogue SMS 201-995 on hepatic haemodynamics in the cirrhotic rat. Br J Surg 1985;72:864-867.
28. Jenkins SA, Baxter JN, Corbett WA. Effects of somatostatin analogue SMS 201-995 on hepatic haemodynamics in the pig and on intravariceal pressure in man. Br J Surg 1985;72:1009-1012.
29. Jenkins SA, Baxter JN, Corbett WA. A prospective randomized controlled clinical trial comparing somatostatin and vasopressin in controlling acute variceal haemorrhage. Br Med J 1985;290:275-278.
30. Sonnnenburg GE, Keller U, Perruchud A. Effects of somatostatin on splanchnic hemodynamics. Gastroenterology 1981;80:5226-5232.
31. Merkel C, Gatta A, Zuin R. Effect of somatostatin on splanchnic hemodynamics in patients with liver cirrhosis and portal hypertension. Digestion 1985;32:92-98.
32. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: Implications for regulation of portal pressure and resistance. Hepatology 1996;24:233-240.
33. Tanoue E, Kitano S, Sugimachi K. A rat model of esophageal varices. Hepatology 1991;13:353-358.
34. Reichen J, Le M. Verapamil favourably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver. J Clin Invest 1986;78:448-455.
35. Marteau P, Ballet F, Chazouilleres O, Chretien Y, Rey C, Petit D, et al. Effect of vasodilators on hepatic microcirculation in cirrhosis: A study in the isolated perfused rat liver. Hepatology 1989;9:820-823.
36. Baldus WP, Hoffbauer FW. Vascular changes in the cirrhotic liver as studied by injection technique. Am J Dig Dis 1963;8:689-692.
37. Reichen J, Hirlinger A, Ha HR, Saegesser H. Chronic verapamil administration lowers portal pressure and improves hepatic function in rats with liver cirrhosis. J Hepatol 1986;3:49-58.